Ty Tuckerman Email & Phone Number

Detroit, MI, US

Michigan, United States

• Responsible for driving business results for rare liver disease medication in hepatology and gastroenterology space with two new branded competitors. Responsible for gaining access in difficult market, changing beliefs.
• 6th in the nation for new enrollments and NBRx with 2 new competitors in the market.
• Significantly exceeding previous territory performance for enrollments, new prescriptions, and overall territory performance.
• Successfully built relationships that opened access to previously inaccessible accounts that delivered new enrollments and NBRx.

Midwest, United States

• Markets: Oncology, Cancer Prevention, Molecular Diagnostics
• 41% YOY growth in late life cycle diagnostic product with no new data.
• Team finished 118% to quota while achieving efficiencies and achieving profitability finishing in the top 40% of the nation.
• Led transformation of culture while delivering high performance measuring in the top 80% of all companies utilizing Gallop.
• Leadership MVP (Q4 2022 and Q1 2023) and Diamond Award Winner (Q1 2023).
• Led account teams that delivered significant growth for diagnostic product within the Midwest based market.

Midwest, United States

• Market Segments: Healthcare, Medical Device, Specialty Pharmacy, Endocrinology
• Ranked 3rd nationally in sales performance.
• Led transformation of culture that established a new standard of high performance focused on establishing need.
• Complicated medical device sale that included changing perception, specialty pharmacy stocking, and in depth patient training.
• Successfully led new team covering 14 states.

Michigan, United States

• Market Segments: Orphan Drug, Rare Disease, Mental Health, Psychiatry, Neurology
• 200% to quota for rare orphan drug during a global pandemic with no sales adjustment.
• Ranked 2nd in the nation two consecutive years (2020 and 2021).
• Consistently selected to lead new hire training based upon results and teaching background.
• All 4 new sales reps exceeded orphan drug sales goal within the first 6 months.
• Collaboratively created the 2021 national corporate selling strategy for Fanapt for 2021.

Michigan, United States

• Market Segments: Specialty Pharma, Integrated Delivery Networks, Gastroenterology, Antibiotics, Infectious Disease, Urology, Dermatology, Endocrinology, Neurology, Psychiatry, Pulmonology, Asthma & Allergy, Peds, and.
• Top 30% or better year-end sales performance in 6 of 7 years. High performance in different markets, selling to different customer segments with portfolio of products that ranged from product launch to late in life.
• Launched 4 new products that exceeded the national benchmarks with supporting documentation despite any significant managed care wins.
• 5 Time National Award Winner
• 5 consecutive years of increased revenue, profitability, and market share with late-stage diabetes product competing against 19 branded competitors.
• Increased revenue $3 Million annually by spearheading regional formulary win.

Detroit Metropolitan Area

• Market Segments: Antibiotics, Infectious Disease, Pulmonology, Urology, Dermatology, Asthma and Allergy, ENT, Pediatrics, and Primary Care.
• Ranked top 15% for inhaled corticosteroid (Asmanex) launch in a highly competitive market.
• Ranked 1st in the nation (out of more than 1500 representatives) with Asmanex for market share change (2007).
• Ranked 1st in the nation (out of more than 1500 representatives) with Foradil for market share change (2007).
• Successfully completed Manager Development Program.
• Rookie of the Year.